Pailing Bio: Wholly owned subsidiary receives acceptance notice for clinical trial application of human thrombin drug

2026-02-22 07:46:33

Pailing Biotech announced that its wholly-owned subsidiary Guangdong Shuanglin Biopharmaceutical Co., Ltd. has received the “Acceptance Notice” (Acceptance Number: XCSL2600060) for the clinical trial application of human thrombin drugs issued by the National Medical Products Administration. The indicated use for human thrombin: for external use only, to assist in hemostasis in cases of capillary and small vein bleeding and minor hemorrhages, when standard surgical techniques to control bleeding are ineffective or impractical. This product can be used in conjunction with absorbable gelatin sponges and other materials.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.